Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study

Maturitas. 1987 Nov;9(3):227-34. doi: 10.1016/0378-5122(87)90005-3.


The effect of Bellergal Retard (BR) on climacteric complaints was evaluated versus a placebo in an 8-wk double-blind study, followed by a 4-wk open study in which only BR was used as medication. There was a marked decrease in complaints in both the BR and the placebo groups. Statistically significant differences were observed between the groups after 2 and 4 wk of treatment, indicating superior results with BR. After 8 wk of study however, these differences were no longer apparent. It was concluded that studies on medication for climacteric complaints should not only be placebo-controlled, but also be of at least 8 to 12 wk duration for proper evaluation.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Belladonna Alkaloids
  • Climacteric / drug effects*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Combinations / adverse effects
  • Drug Combinations / therapeutic use
  • Ergotamines / adverse effects
  • Ergotamines / therapeutic use*
  • Female
  • Humans
  • Methysergide / adverse effects
  • Methysergide / therapeutic use*
  • Middle Aged
  • Phenobarbital / adverse effects
  • Phenobarbital / therapeutic use*
  • Sweating / drug effects


  • Belladonna Alkaloids
  • Drug Combinations
  • Ergotamines
  • belladonna alkaloid, ergotamine, phenobarbital drug combination
  • Methysergide
  • Phenobarbital